[ad_1] Thinly traded micro cap VBI Vaccines (NASDAQ:VBIV) is up 15% premarket on light volume in apparent reaction to its announcement that initial data from its Phase 1/2a clinical trial evaluating VBI-1901 in recurrent …
Read More »VBI Vaccines up 15% ahead of presentation of VBI-1901 data – VBI Vaccines (NASDAQ:VBIV)
